AAO 2024: EyePoint’s EYP-1901 Demonstrates Non-Inferiority to Aflibercept in DAVIO 2 Trial
Sunday, 20 October 2024, 18:56
Overview of AAO 2024 Findings
At the AAO 2024 conference, significant results from the DAVIO 2 trial were presented, showcasing EyePoint's EYP-1901. This treatment option is positioning itself as a formidable alternative to aflibercept.
Trial Results
In the trial, 97% of participants reported adverse events (AEs). However, it is crucial to note that the majority of these incidents were classified as mild to moderate.
Impact on Future Treatments
- Non-Inferiority: EYP-1901 has proven to be non-inferior to aflibercept.
- Potential for broader usage in ocular treatments.
- Implications for patient safety and treatment efficacy.
These results underscore the necessity for ongoing advancements in ophthalmologic therapies and may shape future clinical practices.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.